放疗后前列腺癌复发挽救性高强度聚焦超声:HIFI-2研究
这项在法国32个中心开展的前瞻性全国性研究评估了挽救性高强度聚焦超声(S-HIFU)用于放疗后活检证实的前列腺内复发且无区域或远处转移的患者。2015至2019年共纳入531例,中位年龄75岁,S-HIFU前中位PSA为4.5 ng/ml。30个月无雄激素剥夺治疗生存率为71%(95% CI 67-76),S-HIFU前PSA≤4.5 ng/ml且Gleason评分6-7者30个月ADT-FS达84%(95% CI 78-91)。
要点
- S-HIFU后30个月无ADT生存率为71%,PSA≤4.5 ng/ml且Gleason 6-7者达84%。
- 高级别(>IIIa)并发症19/531例,严重尿失禁从7%增至12%。
- 12个月EORTC QLQ-C30中位评分未见恶化。
核心结论
- 这项大型前瞻性试验表明S-HIFU治疗放疗后局部前列腺癌复发具有良好的肿瘤学和功能学结局。
- S-HIFU前PSA对疗效预测的重要性提示需对适合局部挽救治疗的患者更早发现复发。
研究设计与样本
- 前瞻性、全国性研究,在法国32个中心开展。
- 纳入2015至2019年531例活检证实前列腺内复发、无区域或远处转移的患者。
- 主要终点为无雄激素剥夺治疗生存(ADT-FS)。
- 次要终点包括前列腺癌特异性生存、总生存和功能结局。
主要发现
- S-HIFU时中位年龄75岁,中位PSA为4.5 ng/ml。
- HIFU后12个月和30个月中位PSA分别为0.7和1.02 ng/ml。
- 总体队列30个月ADT-FS为71%(95% CI 67-76)。
- S-HIFU前PSA≤4.5 ng/ml且Gleason评分6-7者30个月ADT-FS为84%(95% CI 78-91)。
- Dindo-Clavien分级>IIIa的高级别并发症报告于19/531例,严重尿失禁病例从7%增至12%。
关键数值与推荐
- 30个月ADT-FS总体为71%(95% CI 67-76)。
- S-HIFU前PSA≤4.5 ng/ml且Gleason评分6-7者30个月ADT-FS为84%(95% CI 78-91)。
- 高级别(>IIIa)并发症19/531例,严重尿失禁从7%增至12%。
临床怎么用
- S-HIFU可作为放疗后前列腺内复发且无转移患者的局部挽救治疗选择。
- S-HIFU前PSA≤4.5 ng/ml且Gleason评分6-7者可能获得更优的ADT-FS。
- 需关注高级别并发症和严重尿失禁风险,治疗前应充分评估。
局限性
- 需进一步研究在不同挽救性局部治疗方案之间开展高水平证据试验比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Management of local prostate cancer (PCa) recurrence after primary radiotherapy (RT) remains challenging in daily practice. Salvage high-intensity focused ultrasound (S-HIFU) represents a valid option, but large prospective data are missing. METHODS: A prospective, nationwide study was conducted in 32 French centers assessing S-HIFU as a local treatment after RT failure in patients with biopsy-confirmed intraprostatic recurrence without regional or distant metastases. The primary endpoint was androgen deprivation therapy-free survival (ADT-FS). Secondary endpoints were PCa-specific survival and overall survival, and functional outcomes. KEY FINDINGS AND LIMITATIONS: From 2015 to 2019, 531 patients were included. Median age and prostate-specific antigen (PSA) at S-HIFU were 75 yr and 4.5 ng/ml, respectively. Median PSA was 0.7 and 1.02 ng/ml at 12 and 30 mo after HIFU, respectively. The 30-mo ADT-FS was 71% in the overall cohort (95% CI, 67-76). A pre-S-HIFU PSA level ≤ 4.5 ng/ml and Gleason score 6-7 had the most favorable ADT- FS rates at 30-mo: 84% (95% CI, 78-91). High-grade (>IIIa) complications graded with the Dindo-Clavien classification were reported in 19/531 patients. The number of cases with severe incontinence increased from 7% to 12% after S-HIFU. The quality-of-life study showed no deterioration in the EORTC QLQC-30 median score at 12 mo. CONCLUSION AND CLINICAL IMPLICATIONS: This large prospective trial demonstrates good oncologic and functional outcomes after S-HIFU for treating local PCa recurrence after RT. The importance of pre-S-HIFU PSA for efficacy prediction highlights the need for earlier detection of recurrence in patients eligible for local salvage treatment. Further studies should focus on comparisons between different salvage local treatment options within high-level evidence trials. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04307056.
引用
- Ploussard G, Coloby P, Chevallier T, et al. Salvage High-intensity Focused Ultrasound for Prostate Cancer Recurrence after Radiotherapy (HIFI-2 Study). Eur Urol Oncol. 2026. PMID: 42055879. doi:10.1016/j.euo.2026.04.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。